Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of pharmaceutical services operator Omnicare (NYSE: OCR) are looking sprightly today, jumping as high as 11.7% above Wednesday's closing price on heavy volume.

So what: Fourth-quarter earnings and sales were in line with analyst projections, and guidance for 2011 didn't impress anybody either. Without positive comments during the conference call, Omnicare's stock would surely have cratered today.

Now what: Sure enough, management used the analyst call to outline a 2011 with strong growth drivers appearing in the second half. Above all, a dozen blockbuster drugs are about to go generic. Other than juicing profits for generics giant Teva Pharmaceutical (Nasdaq: TEVA), that trend will give Omnicare a more profitable margin structure. By 2013, management expects to see double-digital compound annual sales growth and a vastly improved capital structure. The market is reacting to long-term news for once.

Interested in more info on Omnicare? Add it to your watchlist.

Fool contributor Anders Bylund holds no position in any of the companies discussed here. The Fool owns shares of Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool is investors writing for investors.